EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Response to First‐Line Chemotherapy Predicts Response to Maintenance Avelumab Therapy in Japanese Patients With Advanced Urothelial Carcinoma

Satoshi Inoue iD, Akira Hayakawa, Mikinori Kobayashi, Yuriko Nagasaka, Takanao Omi, Noritoshi Shamoto, Fumihiro Ito, Takuma Yuba, Yuri Yuguchi, Hideji Kawanishi, Kosuke Tochigi, Shusuke Akamatsu

International Journal of Urology · 2025

DOI: 10.1111/iju.70162 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Urology, 2025. Verfasst von Satoshi Inoue und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Carcinoma, Transitional Cell, Maintenance Chemotherapy, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

The association between the response to first‐line chemotherapy and maintenance of avelumab remains unclear. We identified factors associated with the response to avelumab in patients with advanced urothelial carcinoma using real‐world data.

Methods

We retrospectively enrolled 100 patients with advanced urothelial carcinoma treated with maintenance avelumab therapy between March 2021 and April 2024 at Nagoya University and nine affiliated hospitals. The complete/partial‐response group was defined as patients with complete response or partial response as the best response to first‐line chemotherapy. The stable disease group was defined as patients with stable disease as the best response to first‐line chemotherapy.

Results

Seven patients (7.0%) achieved complete response, 65 (65.0%) achieved partial response, and 28 (28.0%) achieved stable disease as the best response to first‐line chemotherapy. Regarding avelumab therapy, the complete/partial‐response group had significantly better progression‐free survival than the stable disease group (median: 11.1 vs. 3.2 months, p < 0.001). In multivariate analyses, the best response to first‐line chemotherapy was the only independent risk factor for progression‐free survival (hazard ratio = 1.844, 95% confidence interval = 1.002–3.394; p = 0.049). Overall survival was significantly shorter in the stable disease group than in the complete/partial‐response group (median: 14.1 months vs. not reached, p < 0.001). Multivariate analyses revealed significant associations between poor overall survival and performance status (hazard ratio = 2.175, 95% confidence interval = 1.030–4.592; p = 0.042) and the best response to first‐line chemotherapy (hazard ratio = 4.174, 95% confidence interval = 1.975–8.824; p < 0.001).

Conclusions

The best response to first‐line chemotherapy may predict the clinical outcome of patients with advanced urothelial carcinoma treated with avelumab.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedCarcinoma, Transitional CellMaintenance ChemotherapyAntineoplastic Agents, ImmunologicalUrinary Bladder NeoplasmsUrologic NeoplasmsHumansMaleFemaleAgedRetrospective StudiesJapanMiddle AgedAged, 80 and overProgression-Free SurvivalTreatment OutcomeEast Asian People

Stichwörter der Autor:innen

avelumabcarcinomaimmunotherapyprognosisrisk factors

Substanzen

avelumabAntibodies, Monoclonal, HumanizedAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Department of Urology, Yokkaichi Municipal Hospital, Yokkaichi, Japan.
  • Department of Urology, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital, Nagoya, Japan.
  • Department of Urology, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Japan.
  • Department of Urology, Toyohashi Municipal Hospital, Toyohashi, Japan.
  • Department of Urology, Chukyo Hospital, Nagoya, Japan.

ORCID-Profile: Satoshi Inoue

Zitieren

APA

Inoue, S., Hayakawa, A., Kobayashi, M., Nagasaka, Y., Omi, T., Shamoto, N., Ito, F., Yuba, T., Yuguchi, Y., Kawanishi, H., Tochigi, K., & Akamatsu, S. (2025). Response to First‐Line Chemotherapy Predicts Response to Maintenance Avelumab Therapy in Japanese Patients With Advanced Urothelial Carcinoma. International Journal of Urology. https://doi.org/10.1111/iju.70162

Vancouver

Inoue S, Hayakawa A, Kobayashi M, Nagasaka Y, Omi T, Shamoto N, et al. Response to First‐Line Chemotherapy Predicts Response to Maintenance Avelumab Therapy in Japanese Patients With Advanced Urothelial Carcinoma. International Journal of Urology. 2025. doi:10.1111/iju.70162

BibTeX
@article{Inoue2025,
  author = {Inoue, Satoshi and Hayakawa, Akira and Kobayashi, Mikinori and Nagasaka, Yuriko and Omi, Takanao and Shamoto, Noritoshi and Ito, Fumihiro and Yuba, Takuma and Yuguchi, Yuri and Kawanishi, Hideji and Tochigi, Kosuke and Akamatsu, Shusuke},
  title = {Response to First‐Line Chemotherapy Predicts Response to Maintenance Avelumab Therapy in Japanese Patients With Advanced Urothelial Carcinoma},
  journal = {International Journal of Urology},
  year = {2025},
  doi = {10.1111/iju.70162}
}
Kostenlos starten →